This Article Full Text Full Text (PDF) Other Versions of this Article: IAI.01025-07v1 76/3/1314    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Baldwin, M. R. Articles by Barbieri, J. T. PubMed PubMed Citation Articles by Baldwin, M. R. Articles by Barbieri, J. T.

Subunit Vaccine against the Seven Serotypes of Botulism

Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin,¹ Food Research Institute, University of Wisconsin—Madison, Madison, Wisconsin²

Received 25 July 2007/ Returned for modification 4 September 2007/ Accepted 19 November 2007

Botulinum neurotoxins (BoNTs) are the most toxic proteins for humans and are classified as category A toxins. There are seven serotypes of BoNTs defined by the lack of cross-serotype toxin neutralization. Thus, an effective vaccine must neutralize each BoNT serotype. BoNTs are organized as dichain A-B toxins, where the N-terminal domain (light chain) is a zinc metalloprotease targeting soluble NSF attachment receptor proteins that is linked to the C-terminal domain (heavy chain [HC]) by a disulfide bond. The HC comprises a translocation domain and a C-terminal receptor binding domain (HCR). HCRs of the seven serotypes of BoNTs (hepta-HCR) were engineered for expression in Escherichia coli, and each HCR was purified from E. coli lysates. Immunization of mice with the E. coli-derived hepta-serotype HCR vaccine elicited an antibody response to each of the seven BoNT HCRs and neutralized challenge by 10,000 50% lethal doses of each of the seven BoNT serotypes. A solid-phase assay showed that the anti-hepta-serotype HCR sera inhibited the binding of HCR serotypes A and B to the ganglioside GT1b, the first step in BoNT intoxication of neurons. This is the first E. coli-derived vaccine that effectively neutralizes each of the seven BoNT serotypes.

Published ahead of print on 10 December 2007.

Editor: S. R. Blanke